|Day Low/High||103.11 / 106.92|
|52 Wk Low/High||75.17 / 109.13|
- Five start-up grants totalling $110,000 awarded by CSL Behring
Abstracts include pivotal efficacy and safety data for IDELVION for hemophilia B and AFSTYLA for hemophilia A; AFSTYLA and IDELVION demonstrate CSL Behring's promise to develop and deliver innovative treatments that help patients with serious medical conditions live full lives
Berinert is the only C1 Esterase Inhibitor concentrate approved for on-demand treatment of acute abdominal, facial or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.
NOTE TO EDITORS: On July 31, 2015 the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.
Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2016 results on Tuesday, July 26, 2016 before the market opens.
2016 Interlaken Leadership Awards to Advance Neurological Disorders Research
AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available
The most recent short interest data has been released for the 05/31/2016 settlement date, which shows a 462,715 share increase in total short interest for Carlisle Companies Inc. , to 1,670,050, an increase of 38.33% since 05/13/2016.
Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Micro-Coax, Inc.
Trade-Ideas LLC identified Carlisle Companies (CSL) as a weak on high relative volume candidate
D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be conducting a General Session at KeyBanc's Conference at the InterContinental Hotel in Boston, MA at...
- AFSTYLA is the first and only single-chain product for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available
Carlisle Companies Incorporated (NYSE:CSL) announced today the appointment of Kevin P.
The award recognizes Perreault's leadership, vision and his role in strengthening and promoting the life sciences industry in the region.
#KnockOutFlu Campaign Drove Home the Importance of Flu Vaccination Among College Students
Staying power is underrated by traders but is the lifeblood of long-term investors, Cramer says.
D. Christian "Chris" Koch, President and Chief Executive Officer of Carlisle Companies Incorporated (NYSE:CSL), will be presenting at Oppenheimer's 11 th Annual Industrial Growth Conference at the Westin Grand Central Hotel...
The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.
-- A successful Pharma of the future requires a much different, authentic form of patient engagement
Trade-Ideas LLC identified Carlisle Companies (CSL) as a new lifetime high candidate
Carlisle Companies, Incorporated (NYSE:CSL) reported record first quarter net sales from continuing operations of $794.
- Locally, Company donates 100 trees to Valley Forge National Historical Park to mark centennial anniversary
- More than 1.5 million international units (IUs) of treatments for hemophilia A and/or von Willebrand Disease shipped in advance of World Hemophilia Day
Carlisle Companies Incorporated (NYSE:CSL) will release first quarter 2016 results on Wednesday, April 27, 2016 before the market opens.
-- In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00
The Community-based Local Empowerment for Advocacy Development (LEAD) Grants will help support initiatives in Indiana, Florida, Tennessee, California and Missouri.